Puma Biotechnology | PBYI - Pre Tax Profit


Puma Biotechnology reported $20.61M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Exelixis USD 252.69M 275K Dec/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 482.31M 75.7M Sep/2025
MacroGenics USD 16.82M 52.97M Sep/2025
Moderna USD -187M 631M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -23.07M 47.98M Sep/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
Takeda JPY 133.86B 105.69B Dec/2025
TG Therapeutics USD 25.91M 5.01M Sep/2025
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025